Thyroid Cancer

September 28th 2022

The Oncomine Dx Target Test was granted approval by the FDA as a companion diagnostic for RET fusion–positive thyroid cancer and RET fusion–positive non–small cell lung cancer.

September 13th 2022

Final data from the phase 2 ATLEP trial showed high response rates with a combination of lenvatinib and pembrolizumab in patients with anaplastic and poorly differentiated thyroid cancer.

September 6th 2022

Eric J. Sherman, MD, discussed the effects of using the MEK inhibitor trametinib in combination with paclitaxel in metastatic anaplastic thyroid cancer.

June 27th 2022

A system review and meta-analysis found that the use of radiofrequency ablation for low-risk metastatic papillary microcarcinomas of the thyroid was safe and effective.